TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

78 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

68 studies on the map

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Research Site, TucsonEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases — Stanford Neuroscience Health Center, Palo AltoCD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Children's Hospital of Philadelphia, PhiladelphiaA Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis — Stanford Multiple Sclerosis Center, Palo AltoUS Zamto-cel Autoimmune Diseases — Froedtert Hospital and the Medical College of Wisconsin, MilwaukeePolypill for Prevention of Cardiomyopathy — UT Southwestern Medical Center, DallasA Study of LY3971297 in Healthy Participants — CenExel ACT, AnaheimA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease — Research Site 4, Redwood CityAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Erick H. Alayo Medical Corporation - Gastro SB Clinic, Chula VistaA Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) — Climb Bio Investigative Site #100104, AllenAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghA Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) — University of Colorado Anschutz Medical Campus, AuroraAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab — National Institutes of Health Clinical Center, BethesdaA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease — Wallace Rheumatic Center, Beverly HillsRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus — University of California Irvine, OrangeBAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus — Nationwide Children's, ColumbusTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdaleA Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Stanford University Medical Center, StanfordTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityA Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE — Research Site, San FranciscoA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) — Life Clinical Trials - Colonial Drive - Margate /ID# 276050, MargateA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) — Local Institution - 0011, BirminghamExploring the Utility of [18F]3F4AP for Demyelination Imaging — Yale University PET Center, New HavenMitigating the Pro-inflammatory Phenotype of Obesity — University of Kansas Medical Center, Kansas CityREACT-01: Reversing Autoimmunity Through Cell Therapy — Seattle Children's Hospital, SeattleAlnuctamab for Refractory SLE (LATTE Study) — Icahn School of Medicine at Mount Sinai, New YorkPhase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders — MD Anderson Cancer Center, HoustonA Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants — GSK Investigational Site, ScottsdaleR-3750 in Patients With Mild to Moderate Ulcerative Colitis — Amicis Research Center, ValenciaFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease — Mayo Clinic, PhoenixDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders — H01- Children's National Hospital, Washington D.C.Beta-Hydroxybutyrate Feasibility Treating IBD — University of Texas at Austin, AustinStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) — Pinnacle Research Group /ID# 278677, AnnistonDouble-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus — National Institutes of Health Clinical Center, BethesdaObe-cel in Refractory Progressive Forms of Multiple Sclerosis — Stanford University, Redwood CityAssessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy — Sandler Neurosciences Building, Neurological Clinical Research Unit, San FranciscoNon-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis — University of Washington, SeattleA Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) — Nkarta Investigational Site, Little RockOpen-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. — IRIS Research and Development, LLC, PlantationStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants — Research Site, BirminghamA Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis — Profound Research, LLC, CarlsbadA Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants — US06-0, La PalmaAssessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. — University of Alabama at Birmingham Medical Center, BirminghamA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus — AARA Clinical Research, AvondaleLow Dose IL-2 for the Treatment of Crohn's Disease — Boston Children's Hospital, BostonSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoUC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients — Medical University of South Carolina, CharlestonStudy to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis — The University of Texas Health Science Center at Houston, HoustonCentral Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy — National Institutes of Health Clinical Center, BethesdaMetabolic Effects of Angiotensin-(1-7) — Vanderbilt University Medical Center, NashvillePET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases — Brigham MS Center, 60 Fenwood Road, Boston: Vascular Function in Health and Disease — George E Wahlen VA Medical Center, Salt Lake CityTargeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) — National Institutes of Health Clinical Center, BethesdaMolecular Imaging of NET Using [C-11]MRB-PET in MS — Brigham MS Center, 60 Fenwood Road, BostonTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamPilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy — Connecticut Children's Medical Center, HartfordStem Cell Transplantation in Crohn's Disease — Cedars-Sinai Medical Center, Los AngelesHyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease — University of Kansas Medical Center, Kansas CityInvestigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects — Massachusetts General Hospital, BostonSympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study) — University of Kansas Medical Center, Kansas CitySympathetic Mechanisms in Obesity-Crossover Design — Vanderbilt University Medical Center, NashvilleEarly Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor — Lucile Packard Children's Hospital, Palo AltoVancomycin Study in Multiple Sclerosis (MS) — Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New YorkA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. — Research Site, AnnistonDose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis — Mayo Clinic, Rochester